Price3.14%   +10.16
(After Hours: 334.00 +0.22 +0.07% )

Vertex Pharmaceuticalsrpor Stock (VRTX) Latest News

May-31-23 11:30AM Why Is Vertex (VRTX) Down 6% Since Last Earnings Report?Zacks Investment Research
10:05AM Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire RicherThe Motley Fool
May-31-23 07:45AM CRISPR Therapeutics: A Galaxy's Worth of Deep ValueThe Motley Fool
06:20AM Should You Invest in the VanEck Biotech ETF (BBH)?Zacks Investment Research
May-30-23 01:01AM Expert Ratings for Vertex PharmaceuticalsBenzinga
11:00AM Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023Benzinga
May-04-23 10:38AM 1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in MayThe Motley Fool
05:32AM 2 Potentially Explosive Stocks to Buy in MayThe Motley Fool
May-04-23 05:30AM 3 Top Healthcare Stocks to Buy in MayThe Motley Fool
May-03-23 10:15AM Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals StockThe Motley Fool
06:20AM Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?Zacks Investment Research
May-03-23 05:50AM 7 Reasons to Buy Vertex Pharmaceuticals Stock NowThe Motley Fool
May-02-23 05:01AM Analyst Expectations for Vertex Pharmaceuticals's FutureBenzinga
02:00AM Vertex Pharmaceuticals Just Lost a Potential Rival. Is the Stock a Buy?The Motley Fool
May-02-23 01:00AM Baird Maintains Neutral Rating for Vertex Pharmaceuticals: Here's What You Need To KnowBenzinga
12:49PM CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?Zacks Investment Research
May-02-23 12:06PM Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/YZacks Investment Research
10:00AM 2 Supercharged Stocks to Buy for 2023 and Hold for at Least 10 YearsThe Motley Fool
May-02-23 09:09AM 2 Incredible Growth Stocks That Could Turn $20,000 Into $100,000 by 2030The Motley Fool
05:50AM Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVieThe Motley Fool
May-01-23 09:30AM Vertex Pharmaceuticals (VRTX) Q1 2023 Earnings Call TranscriptThe Motley Fool
11:00AM ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake EncouragingZacks Investment Research
May-01-23 05:50AM The Best Stocks to Invest $5,000 in Right NowThe Motley Fool
Apr-28-23 03:28AM Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?Zacks Investment Research
Apr-27-23 10:23AM 2 Growth Stocks That Could Double in 5 YearsThe Motley Fool
03:30AM Cytek Biosciences, Inc. (CTKB) Soars 13.4%: Is Further Upside Left in the Stock?Zacks Investment Research
Apr-25-23 05:45AM Vertex Pharmaceuticals (VRTX) Stock Moves -0.27%: What You Should KnowZacks Investment Research
10:01AM Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research
Apr-25-23 09:45AM This Supercharged Dividend King Stock Might Soon Run Out of SteamThe Motley Fool
Apr-24-23 05:50AM Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research
02:00AM 3 Healthcare Stocks That Could Help Make You a FortuneThe Motley Fool
Apr-24-23 01:49AM With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023Benzinga
10:00AM Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to DeclineZacks Investment Research
Apr-24-23 07:10AM The Zacks Analyst Blog Highlights Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCIZacks Investment Research
Apr-21-23 04:20AM Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards LifesciencesZacks Investment Research
09:49AM Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?Zacks Investment Research
Apr-21-23 07:59AM Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades'Benzinga
Apr-20-23 02:00AM Better Big Biotech Buy: Biogen vs. VertexThe Motley Fool
10:15AM Have $1,000? 2 Explosive Growth Stocks to Buy and Hold No Matter What the Market Does NextThe Motley Fool
Apr-17-23 05:56AM Which Stocks Pass Warren Buffett's $10,000 Test?The Motley Fool
05:50AM Prediction: These Will Be 3 of the Biggest Monster Stocks of the DecadeThe Motley Fool
Apr-14-23 10:23AM Is CRISPR Therapeutics Stock a Buy Now?The Motley Fool
Apr-13-23 10:15AM 2 Nasdaq Growth Stocks That Are Screaming Buys in AprilThe Motley Fool
08:34AM Moderna, ConocoPhillips, Vertex Pharmaceuticals And This ETF: CNBC's 'Final Trades'Benzinga
Apr-12-23 05:50AM Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should KnowZacks Investment Research
05:30AM Could This Move Make Vertex's Next Blockbuster Even Bigger?The Motley Fool
Apr-10-23 05:54AM My 5 Top Stocks to Buy in AprilThe Motley Fool
Apr-07-23 10:15AM 2 Once-in-a-Decade Buying Opportunities in a Growth Stock Bear MarketThe Motley Fool
05:41AM A Bull Market Is Coming: 2 Unstoppable Growth Stocks to Scoop Up Right NowThe Motley Fool
Apr-06-23 09:37AM 2 Smartest Growth Stocks to Buy Without Hesitation Right NowThe Motley Fool
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Cap:     |  Volume (24h):